Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1–CH3 fusion protein

Zeyan Pan, Zonghai Li, Zhimin Shi et al.|Cancer Immunology Immunotherapy|2018

Cited by 63